Int Clin Psychopharmacol 2017 Nov;32(6):350-355
aDepartment of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine, University of Chicago, Chicago, Illinois bDepartment of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts cDepartment of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA dSchool of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen eH. Lundbeck A/S, Copenhagen fDepartment of Psychiatry, University of Cambridge gCambridge and Peterborough NHS Foundation Trust, Cambridge, UK hDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.
Trichotillomania is a functionally impairing, often overlooked disorder with no Food and Drug Administration-approved medications indicated for its treatment. The ability of clinical trials to detect the beneficial effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo response rate. Very little is known about baseline demographic and clinical characteristics that may be predictive of placebo response in such patients. Read More